Assessment of the therapeutic value of new medicines marketed in Australia.
作者信息
Wonder Michael J
机构信息
Wonder Drug Consulting, Sydney, NSW, Australia.
出版信息
J Pharm Policy Pract. 2013 Sep 10;6:7. doi: 10.1186/2052-3211-6-7. eCollection 2013.
Abstract
摘要
相似文献
1
Assessment of the therapeutic value of new medicines marketed in Australia.对在澳大利亚上市的新药的治疗价值评估。
J Pharm Policy Pract. 2013 Sep 10;6:7. doi: 10.1186/2052-3211-6-7. eCollection 2013.
2
Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'.对迈克尔·旺德就《澳大利亚上市新药治疗价值评估》一文发表的评论的回应。
J Pharm Policy Pract. 2013 Oct 10;6:8. doi: 10.1186/2052-3211-6-8. eCollection 2013.
3
The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.澳大利亚治疗用品管理局以及新西兰药品与医疗器械安全管理局在评估补充和替代药物方面所发挥的作用。
Toxicology. 2006 Apr 3;221(1):88-94. doi: 10.1016/j.tox.2005.12.023. Epub 2006 Feb 14.
4
Access to new medicines in New Zealand compared to Australia.新西兰与澳大利亚在获取新药方面的比较。
N Z Med J. 2011 Nov 25;124(1346):12-28.
5
What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).“传统”经济评估对患者获取新型孤儿药有何影响？澳大利亚药品报销情况的比较研究（2005 - 2012年）
Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):843-50. doi: 10.1586/14737167.2015.1042368. Epub 2015 May 4.
6
Managed entry agreements for pharmaceuticals in Australia.澳大利亚药品的有条件市场进入协议。
Health Policy. 2014 Sep;117(3):345-52. doi: 10.1016/j.healthpol.2014.05.005. Epub 2014 Jun 2.
7
The regulation of herbal medicines in Australia.澳大利亚的草药监管。
Toxicology. 2002 Dec 27;181-182:565-70. doi: 10.1016/s0300-483x(02)00483-3.
8
Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.两国患者获取药品情况比较：卫生体制相似，药品政策不同——基于全面文献回顾的结果
Res Social Adm Pharm. 2019 Mar;15(3):231-243. doi: 10.1016/j.sapharm.2018.04.006. Epub 2018 Apr 13.
9
Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.探索固定预算对新药的影响：澳大利亚和新西兰新药报销情况研究
Aust Health Rev. 2015 Sep;39(4):455-461. doi: 10.1071/AH14122.
10
Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study.澳大利亚和新西兰癌症药物获取项目：一项探索性研究。
Health Policy. 2018 Mar;122(3):243-249. doi: 10.1016/j.healthpol.2017.12.004. Epub 2017 Dec 20.
本文引用的文献
1
Assessment of the therapeutic value of new medicines marketed in Australia.对在澳大利亚上市的新药的治疗价值评估。
J Pharm Policy Pract. 2013 Jun 13;6:2. doi: 10.1186/2052-3211-6-2. eCollection 2013.
Zotero 插件